M&A – Talk Bio

Actionable Insights Powered by AI

Alkermes Ups Bid for Avadel Amid Lundbeck’s Competing Offer in Narcolepsy Drug Takeover Battle

3 weeks ago talkbio0Tagged Acquisition, Alkermes, Avadel Pharmaceuticals, bidding war, contingent value right, LUMRYZ, Lundbeck, M&A, Narcolepsy, Pharma, Primary Hypersomnia

Alkermes; Avadel Pharmaceuticals; Lundbeck; bidding war; Lumryz; narcolepsy; acquisition; contingent value right; pharma M&A; idiopathic hypersomnia

Novo Nordisk Ups Metsera Bid to $10 Billion to Top Pfizer’s Offer

1 month ago talkbio0Tagged Acquisition, contingent value right, Diabetes, M&A, Metsera, Novo Nordisk, Obesity, Pfizer

Novo Nordisk; Metsera; Pfizer; M&A; biotech acquisition; contingent value right; obesity drugs; diabetes treatments

Recent News: Live at 11 a.m. ET – M&A, FDA, MFN and Collaboration with FT

1 month ago talkbio0Tagged Acquisitions, Drug Approval, Economics, Financial Times, Live - Specimen Condition, M&A, mergers, MFN, News [Publication Type], United States Food and Drug Administration

M&A; FDA; MFN; Financial Times; mergers and acquisitions; drug approval; economics; live news

Are the Good Times in Biotech Back? – Insights from Post-Hoc Live’s 2025 Industry Sentiment

2 months ago talkbio0Tagged Aggressive Periodontitis, delays, executive survey, Funding, Industry, M&A, Post-Hoc Live, public biotech, Sentiment, United States Food and Drug Administration

biotech sentiment; Post-Hoc Live; 2025 industry outlook; biotech M&A; FDA delays; executive survey; public biotech companies; JP Morgan effect; biotech funding

Biopharma Deal Activity Shows Uptick in Q3 2025: Signs of Recovery and Emerging Trends

2 months ago talkbio0Tagged assets, Biopharma, China, Early-stage, Europe, Licensing, M&A, Merus, Metsera, Physical activity, Q3, therapeutic diversification, U.S., Verona Pharma

biopharma; Q3 2025; deal activity; M&A; licensing; therapeutic diversification; early-stage assets; China; US; Europe; Metsera; Verona Pharma; Merus; high-value deals

Pfizer’s $4.9B Metsera Deal Signals More Pharma M&A in Booming Obesity Drug Market

3 months ago talkbio0Tagged biotech acquisition, Glucagon-Like Peptide 1, late-stage clinical development, M&A, Metsera, Obesity, Pfizer, Pharma, pharmaceutical market, Weight Loss

Pfizer; Metsera; obesity drugs; weight loss; pharma M&A; GLP-1; biotech acquisition; pharmaceutical market; late-stage clinical development

Royalty Market Accelerates with XOMA Biotech Acquisitions and OrbiMed’s Major Fundraise

4 months ago talkbio0Tagged Arenaria, Biological Factors, Biological Science Disciplines, biopharma financing, Conditional, HilleVax, Investments, LAVA, M&A, mezigitamab, OrbiMed, royalty acquisition, XOMA Royalty

royalty acquisition; XOMA Royalty; biotech M&A; OrbiMed; biopharma financing; mezigitamab; Turnstone Biologics; HilleVax; LAVA Therapeutics; contingent value rights; life sciences investment

Struggling Biotechs Face Harsh Market as Funding and Clinical Successes Dry Up in 2025

6 months ago talkbio0Tagged Biotech Layoffs, biotech sector, Clinical Trial Failures, downturn, investor sentiment, M&A, Market

biotech layoffs; market downturn; funding challenges; clinical trial failures; investor sentiment; M&A slowdown; job cuts; biotech sector

Pfizer’s Bourla is ‘cautiously optimistic’ on tariffs, says M&A is on the table

7 months ago talkbio0Tagged Bourla, M&A, Pfizer, Policy, tariffs, TNFRSF19 gene, United States

Bourla, M&A, Pfizer, United States, TNFRSF19 gene, Policy, tariffs

Concentra’s Surprise Bid Disrupts Acelyrin-Alumis Merger Plans

10 months ago talkbio0Tagged Acelyrin, Alumis, biopharmaceutical industry, Concentra Biosciences, Disruption, M&A, Merger, Unsolicited Adverse Event

Concentra Biosciences, Acelyrin, Alumis, merger disruption, unsolicited offer, biopharmaceutical industry, M&A